Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 .
ObsEva SAApril 27, 2021 GMT
-
women
Phase 3
-
GENEVA, Switzerland and BOSTON, MA – April 27, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the initiation of the observational PRIMROSE 3 study. PRIMROSE 3 will evaluate long-term bone mineral density (BMD) in subjects who completed at least 20 weeks of treatment in the Phase 3 PRIMROSE 1 (US only) and PRIMROSE 2 (Europe and EU) studies.
“GnRH antagonists are an exciting new therapeutic approach for the treatment of uterine fibroids. In the setting of dose-dependent reductions in estradiol, it is important to understand changes in bone mineral density following treatment, especially amongst potentially
April
27
, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced the initiation of the observational PRIMROSE 3 study. PRIMROSE 3 will evaluate long-term bone mineral density (BMD) in subjects who completed at least 20 weeks of treatment in the Phase 3 PRIMROSE 1 (US only) and PRIMROSE 2 (Europe and EU) studies. GnRH antagonists are an exciting new therapeutic approach for the treatment of uterine fibroids. In the setting of dose-dependent reductions in estradiol, it is important to understand changes in bone mineral density following treatment, especially amongst potentially perimenopausal women, said Felicia Cosman, M.D., a leading expert in bone health and professor of medicine at Columbia University. I look forward to seeing informative data from the PRIMROSE 3 study which will provide insights for women and practitioners on the long-term effects on bon
Calliditas Therapeutics 2020 Annual Report Published
News provided by
Share this article
Share this article
STOCKHOLM, April 27, 2021 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company s website: www.calliditas.com.
This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14:30 CET on April 27, 2021.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: [email protected]
About Calliditas
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas lead product candidate, Nefecon
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ReelTime TV Channels Adding 50 Million Amazon Fire TV Users to Roku’s 51.2 Million Monthly .
ReelTime Rentals, Inc.April 27, 2021 GMT
SEATTLE, WA, April 27, 2021 (GLOBE NEWSWIRE) via NewMediaWire ReelTime VR/ReelTime Media (OTC:RLTR) has confirmed that it is set to launch ReelTime Media channels on the Amazon Fire TV streaming platform. The ReelTime TV channels have begun showing up on Roku as announced last week and will be viewable on Amazon Fire TV in the coming weeks.
The “ReelTime TV” channels will join known cable commodities now available such as ESPN, CBS, NBC, AMC, HGTV, CNN, and others who have launched channels on Amazon Fire TV. The ReelTime TV channels will contain a combination of ReelTime Media original programming as well as serving up additional other cutting-edge content. Along with the U.S., Fire TV is in key territories like Mexico, Brazil, India, J
50 Million Amazon Fire TV Users to Gain ReelTime TV Channels Adding to Rokus 51 2 Million Monthly Active Users Exceeding Cable, Satellite Combined phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.